Persistent URL of this record https://hdl.handle.net/1887/122834
In Collections
This item can be found in the following collections:
A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
- All authors
- Krajewska, J.; Robinson, B.G.; Keam, B.; Capdevila, J.; Klochikhin, A.; Gan, H.; Kapiteijn, E.; Elisei, R.; Partyka, J.; Borgman, A.E.; Schlumberger, M.
- Date
- 2018-10-01
- Title of host publication
- Annals of Oncology
- Volume
- 29
- Pages
- 647 - 648